11.06.2013 - Bill Gates and EU Research Commissioner Máire Geoghegan-Quinn have signed a partnership to fight neglected diseases.
The multibillion partnership of the Bill & Melinda Gates Foundation and the European Commission aims at fighting and other poverty-related diseases such as HIV/AIDS, tuberculosis malaria, lymphatic filariasis or sleeping sickness, which affect more than one billion people globally. "The foundation is completely committed to supporting efforts to develop life-saving products to help solve some of the world’s toughest problems“, said Gates. The partnership will develop at least one improved product per year, according to Geoghegan-Quinn.
Much of the work will be carried out through the European and Developing Countries Clinical Trials Partnership (EDCTP), which so far involves 16 European and 30 sub-Saharan African countries. The European Commission has proposed funding of up to €1 bn from the EU budget to match the contributions of the European partner countries.
Between 2007 and 2011, Gates and the EU invested around €2.4bn in R&D on neglected infectious diseases. Under the agreement, the partners will develop new drugs, vaccines and diagnostics suited to the needs of the population of poor countries , improve health systems and ensure the delivery of such products. Furthermore, the Gates Foundation and the Commission will launch a joint innovation prize in 2014 in order to honour current approaches to global health.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
JANUS® G3 Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 μl to 5000 μl for consistent and reproducible sample preparation more